$PHR

Rosen Law Firm filed a securities class action against Phreesia ($PHR) alleging false statements about slowing demand and weak pharmaceutical marketing commitments between May 2025 and March 2026.

Phreesia stock crashes 26.6% after March 2026 revenue guidance cut; securities fraud investigation launched into disclosure practices.

Rosen Law Firm files securities class action against FS KKR Capital ($FSK) alleging portfolio valuation and distribution misstatements, with July 6, 2026 lead plaintiff deadline.

$PHR faces federal securities investigation after announcing disappointing fiscal 2027 guidance, triggering a sharp stock decline that has prompted shareholder litigation.

Robbins LLP launches class action against $PHR for allegedly misleading investors on Network Solutions growth and revenue outlook. Lead plaintiff deadline: July 13, 2026.

Class action lawsuit filed against $PHMD alleging securities fraud. Company allegedly misrepresented business prospects while facing slowing demand and weakened pharmaceutical commitments.

Schall Law Firm seeks $PHR investors in class action over alleged false statements on growth outlook and FY2027 projections.

Phreesia faces securities lawsuit over alleged false statements about revenue visibility; 26.56% stock decline follows March 2026 guidance cut. July 13, 2026 lead plaintiff deadline.

Pomerantz LLP investigates Phreesia after 26.56% stock decline following March 30 revenue guidance cut due to pharma marketing weakness and Networking Solutions visibility issues.

Phreesia stock crashed nearly 50% in Q1 2026 on guidance cuts, but 16% revenue growth, sustained profitability, and 200% free cash flow surge suggest potential rebound.